Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant for reduction of corticosteroid use in severe asthma
NCT03629249Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Countries
- 21
01
Overview
A Phase 3 trial of fevipiprant in severe asthma, sponsored by Novartis. Started Dec 2018; status: terminated.
02
Drugs
fevipiprant
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT03629249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629249.